Hunter Immunology: International Medical Experts Recognise Benefit Of Australian COPD Treatment
· International panel reviews Australian trial
· HI-164OV clinical data published in CHEST Journal
Sydney, 22 April 2010: A landmark trial into a new treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) has shown positive results, with international medical experts now recognising the treatment's promise.
Sydney-based biotechnology company, Hunter Immunology Limited trialled its lead product, an immunotherapeutic known as HI-1640V on forty patients with the debilitating respiratory disorder at four major Australian hospitals, including the Royal Perth Hospital and the Sir Charles Gardiner Hospital.
Now following a review of trial data, doctors at the American College of Chest Physicians have deemed the paper based on research in the first-in-class technology to be of significant value. The paper reports that sufferers trialling the therapy required fewer antibiotics and fewer hospital admissions.
In the prestigious CHEST publication, the researchers noted hospital admissions were cut by 90 per cent, while moderate to severe exacerbations of the illness, like bronchitis, reduced by 63 per cent.
The authors noted: "While the protective effect of HI-I64OV needs to be confirmed in larger studies ...the results show a potential to improve health and reduce the economic burden of acute exacerbations in COPD."
Hunter Immunology's novel therapy works by stimulating the immune system to fight the incidence and severity of acute bronchitis in patients with the disease, which is expected to be the world's third largest cause of death by 2020.
Managing director Dr Kevin Healey said recognition from the CHEST panel was sound acknowledgement of the company's technology.
"This paper validates the safety and efficacy of our product," he said. "Patients who trialled our technology required fewer drugs, fewer antibiotics and had a much lower rate of hospitalisation."
Dr Healey paid patients in the next stage trial would be immunised from February 2011 until April 2011, to prevent exacerbations in the COPD peak season, which is typically in the winter months.
COPD is expected to be the world's third largest cause of death within 10 years. Contact Kevin Healey Hunter Immunology +61 409 413 402 firstname.lastname@example.org
Emma Power Monsoon Communications +61 3 9620 3333 email@example.com
About Hunter Immunology Hunter Immunology is a Sydney-based biotechnology company focused on new treatments for respiratory diseases including Chronic Obstructive Pulmonary Disease (COPD) and Asthma. Its lead product HI-164OV, works by stimulating the immune system to fight the incidence and severity of acute bronchitis in patients with COPD, which is currently the world’s fourth largest cause of death. Two Phase IIa trials have already been completed. The company has lodged an IND with the US Food and Drug Administration to embark on a more extensive clinical trial. Globally COPD is a major cause of disability, hospital admissions and death. The estimated cost of drugs in the US to treat and manage COPD is approximately $US5 billion per annum with associated medical costs estimated at over $US37 billion annually.
Monsoon Communications Level 1 350 Collins Street Melbourne VIC 3000 Ph: 03 9620 3333 www.monsoon.com.au<http://www.monsoon.com.au> This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply e-mail. No warranty is made that the e-mail or attachment(s) are free from computer virus or other defect. *If you wish to be removed from our contact list please send an email to firstname.lastname@example.org
Posted: April 2010